Medexus_Pharma_MPI_PMS_Logo.jpg
Medexus and MidCap Agree to Increase in MidCap’s Revolving Loan Commitment Amount
September 29, 2022 17:05 ET | Medexus Pharmaceuticals Inc
Medexus’s borrowing capacity under its revolving credit facility increases byUS$5.0 million, from US$20.0 million to US$25.0 million Transaction strengthens Medexus’s balance sheet, providing...
Medexus_Pharma_MPI_PMS_Logo.jpg
Medexus Provides Update on Treosulfan NDA Resubmission and Provides Business Update
September 19, 2022 08:00 ET | Medexus Pharmaceuticals Inc
FDA requests further information from medac, continues to engage with treosulfan NDA Medexus continues to focus on maintaining momentum and growth in its North American on-market portfolio, and is...
Medexus_Pharma_MPI_PMS_Logo.jpg
Medexus Holds Annual Meeting of Shareholders and Announces Election of Board of Directors
September 15, 2022 17:05 ET | Medexus Pharmaceuticals Inc
All director nominees reelected for the coming yearAll other proposals also approved by shareholders TORONTO and CHICAGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus)...
Medexus_Pharma_MPI_PMS_Logo.jpg
Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022
August 08, 2022 17:00 ET | Medexus Pharmaceuticals Inc
Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2 Treosulfan NDA resubmitted to the FDA, regulatory milestone payments deferred to October 2023 ...
Medexus_Pharma_MPI_PMS_Logo.jpg
Medexus Schedules First Quarter 2023 Conference Call
August 02, 2022 17:00 ET | Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 9, 2022...
Medexus_Pharma_MPI_PMS_Logo.jpg
Treosulfan NDA Resubmitted to FDA
July 25, 2022 07:00 ET | Medexus Pharmaceuticals Inc
FDA decision expected within six months of acceptancePivotal phase 3 clinical trial of treosulfan met primary endpoint and key secondary endpoints TORONTO and CHICAGO, July 25, 2022 (GLOBE...
Medexus_Pharma_MPI_PMS_Logo.jpg
Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)
June 22, 2022 17:50 ET | Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, June 22, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update...
Medexus_Pharma_MPI_PMS_Logo.jpg
Medexus Schedules Fourth Quarter and Fiscal Year 2022 Conference Call
June 14, 2022 16:30 ET | Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 23, 2022...
Medexus_Pharma_MPI_PMS_Logo.jpg
Treosulfan Pivotal Study Results Published
June 06, 2022 08:30 ET | Medexus Pharmaceuticals Inc
Study’s primary endpoint and key secondary endpoints were metStudy found event-free survival and overall survival superior after treosulfan compared to RIC busulfan, also found non-relapse mortality...
Medexus_Pharma_MPI_PMS_Logo.jpg
Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA
May 24, 2022 17:05 ET | Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, May 24, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, a strategic partner of Medexus, that medac received...